Amphastar Pharmaceuticals Inc Revenue Growth Rates (AMPH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Amphastar Pharmaceuticals Inc   (NASDAQ: AMPH)
 

AMPH's Revenue Growth by Quarter and Year

Amphastar Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AMPH/growth
https://api.csimarket.com/api/v1/companies/AMPH/fundamentals
https://api.csimarket.com/api/v1/companies/AMPH/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
AMPH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 207.61
2nd Quarter June 183.90
1st Quarter March 171.17
FY 562.68

AMPHs Annual Revenue
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 719.89 millions
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 731.97 millions
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 644.40 millions
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 498.99 millions
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 437.77 millions




AMPH Revenue third quarter 2026 Y/Y Growth Comment
Amphastar Pharmaceuticals Inc reported Revenue growth of 8.22% year on year in the third quarter 2026, to $ 207.61 millions, this is lower than Amphastar Pharmaceuticals Inc 's recent average Revenue increase of 10.8%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue growth. While Amphastar Pharmaceuticals Inc ' s Revenue increase of 8.22% ranks overall at the positon no. 2241 in the third quarter 2026.


AMPH Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 8.22 %
2nd Quarter June 5.44 %
1st Quarter March 0.38 %
FY   -

Financial Statements
Amphastar Pharmaceuticals Inc 's third quarter 2026 Revenue $ 207.61 millions AMPH's Income Statement
Amphastar Pharmaceuticals Inc 's third quarter 2025 Revenue $ 191.84 millions Quarterly AMPH's Income Statement


AMPH Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 12.89 %
2nd Quarter June 7.44 %
1st Quarter March -6.52 %
FY (Year on Year)   -


Back to AMPH Growth rate Comparisons >> Back to AMPH Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #325
Overall #2241

Revenue Y/Y Growth Statistics
High Average Low
50.3 % 10.8 % -21.63 %
(Jun 30 2024)   (Sep 30 2017)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #325
Overall #2241
Revenue Y/Y Growth Statistics
High Average Low
50.3 % 10.8 % -21.63 %
(Jun 30 2024)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Amphastar Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
23.91 % 2.88 % -22.81 %
(Sep 30 2023)  


AMPH's III. Quarter Q/Q Revenue Comment
Amphastar Pharmaceuticals Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 12.89%, to $ 207.61 millions, from $183.90 millions in the second quarter.
AMPH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Amphastar Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 970.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #145
Overall #970
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #145
Overall #970
Revenue Q/Q Growth Statistics
High Average Low
23.91 % 2.88 % -22.81 %
(Sep 30 2023)  


AMPH's III. Quarter Q/Q Revenue Comment
Amphastar Pharmaceuticals Inc achieved in the III. Quarter 2026 above company average sequential Revenue rise of 12.89%, to $ 207.61 millions, from $183.90 millions in the second quarter.
AMPH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Amphastar Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 970.


Amphastar Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 730.02
Y / Y Revenue Growth (TTM) 0.76 %
Year on Year Revenue Growth Overall Ranking # 2465
Seqeuential Revenue Change (TTM) 1.32 %
Seq. Revenue Growth (TTM) Overall Ranking # 2712


Cumulative Revenue growth Comment
Although Amphastar Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 11.39% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 0.76% year on year, from -1.63% in Mar 31 2026.

In the Healthcare sector 353 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1078 to 2465.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 354
Overall # 2465

Revenue TTM Y/Y Growth Statistics
High Average Low
31.8 %
 11.39 %
-9.39 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 388
S&P 500 # 2712
Cumulative Revenue growth Comment
Although Amphastar Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 11.39% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 0.76% year on year, from -1.63% in Mar 31 2026.

In the Healthcare sector 353 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1078 to 2465.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 354
Overall # 2465

Revenue TTM Y/Y Growth Statistics
High Average Low
31.8 %
11.39 %
-9.39 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 388
S&P 500 # 2712




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AMPH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions
Medicinova Inc 12.35%$ 12.355 millions
Bionano Genomics Inc 12.34%$ 12.339 millions
Viemed Healthcare Inc 12.18%$ 12.180 millions
Ufp Technologies Inc 12.15%$ 12.154 millions
Innovage Holding Corp 12.14%$ 12.135 millions
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions
Ocugen Inc 11.36%$ 11.358 millions
Dexcom Inc 11.26%$ 11.263 millions
Elanco Animal Health Incorporated11.26%$ 11.258 millions
Koru Medical Systems Inc 11.19%$ 11.194 millions


About Amphastar Pharmaceuticals Inc Revenue Growth Rates (AMPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Amphastar Pharmaceuticals Inc (CIK 1297184).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001297184-26-000053
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Amphastar Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.